New hope for rectal cancer patients: Triple-Threat treatment trial

NCT ID NCT07281768

Summary

This study tests whether adding newer immunotherapy drugs to standard chemotherapy before surgery works better for rectal cancer that hasn't spread. Researchers will compare three different drug combinations in 66 patients to see which helps shrink tumors most effectively with acceptable side effects. The goal is to improve outcomes so patients might avoid more extensive surgery or have better long-term results.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland, 21287, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.